Immunotherapy-Chemo cocktail shows promise for Tough-to-Treat throat cancer

NCT ID NCT06457503

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 5 times

Summary

This study is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy (cisplatin and gemcitabine) can help people with recurrent or metastatic nasopharyngeal cancer that hasn't been treated before. About 100 participants will receive the combination intravenously every three weeks. The main goal is to see how many patients' tumors shrink or disappear, with secondary goals looking at how long that effect lasts and how long people live without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
toripalimab (an immunotherapy drug) combined with cisplatin and gemcitabine (chemotherapy drugs)
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with recurrent metastatic nasopharyngeal cancer, potentially improving response rates and delaying disease progression.
What could go wrong
This is a single-arm, non-randomized study, so results may be less reliable than a randomized trial. Side effects from chemotherapy and immunotherapy can be significant, and the treatment may not work for all participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCER RECURRENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boston Medical Center

    RECRUITING

    Boston, Massachusetts, 02118, United States

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Emory Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

  • Froedtert Hospital and the Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

  • Henry Ford Cancer Center

    RECRUITING

    Detroit, Michigan, 48202, United States

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    WITHDRAWN

    New York, New York, 10016, United States

  • Penn State Milton S. Hershey Medical Center

    RECRUITING

    Hershey, Pennsylvania, 17033, United States

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Canada, MSG 1Z5, Canada

  • University of Arkansas for Medical Sciences

    RECRUITING

    Little Rock, Arkansas, 72205, United States

  • University of California, Irvine

    RECRUITING

    Irvine, California, 92697, United States

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94115, United States

  • University of Cincinnati Medical Center

    RECRUITING

    Cincinnati, Ohio, 45219, United States

  • University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.